Last reviewed · How we verify
IPTp-SP
IPTp-SP is a combination of intermittent preventive treatment using sulfadoxine-pyrimethamine to prevent malaria infection in pregnant women by inhibiting folate synthesis in the malaria parasite.
IPTp-SP is a combination of intermittent preventive treatment using sulfadoxine-pyrimethamine to prevent malaria infection in pregnant women by inhibiting folate synthesis in the malaria parasite. Used for Malaria prevention in pregnant women (intermittent preventive therapy).
At a glance
| Generic name | IPTp-SP |
|---|---|
| Also known as | Fansidar, SP |
| Sponsor | Kenya Medical Research Institute |
| Drug class | Antifolate antimalarial combination |
| Target | Dihydrofolate reductase (DHFR) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | FDA-approved |
Mechanism of action
IPTp-SP (Intermittent Preventive Therapy in pregnancy with Sulfadoxine-Pyrimethamine) works by administering therapeutic doses of the antimalarial drug sulfadoxine-pyrimethamine at scheduled intervals during pregnancy. Sulfadoxine-pyrimethamine inhibits dihydrofolate reductase in Plasmodium parasites, disrupting folate metabolism and preventing parasite replication. This approach reduces parasitemia, placental malaria, and associated adverse pregnancy outcomes including low birth weight and maternal anemia.
Approved indications
- Malaria prevention in pregnant women (intermittent preventive therapy)
Common side effects
- Nausea
- Vomiting
- Abdominal discomfort
- Rash
Key clinical trials
- Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda (PHASE3)
- Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan (PHASE3)
- Chemoprevention Efficacy Study in Burkina Faso (PHASE4)
- TIPTOP Sulfadoxine-pyrimethamine (SP) Drug Resistance Study
- The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract (PHASE3)
- Additional Screening With Sensitives RDTs and Malaria (PHASE3)
- Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) (PHASE3)
- Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |